1
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Cubist Pharmaceuticals is a company with 1 orphan drug designation across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute hepatitis B virus infection | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab | Des.TrialAppr. |
| hepatitis B virus infection | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab | Des.TrialAppr. |
| hepatitis D virus infection | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio